Displaying 1 - 3 of 3
| Active Ingredient | MOCLOBEMIDE |
| Therapeutic Class | MONOAMINE OXIDASE INHIBITORS |
| Indications | Depression, social anxiety disorder. |
| Caution | Sleep disturbances, dizziness, agitation, feelings of anxiety , restlessness, irritability, headache. |
| Dose Range |
Adult: Depression: Initially 300 mg daily in divided doses, adjusted according to response; usual dose 150–600 mg daily after a meal.Anxiety: Initially 300 mg daily for 3 days, then increased to 600 mg daily in 2 divided doses continued for 8-12 weeks to |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MONOAMINE OXIDASE INHIBITORS |
| Therapeutic Class | MONOAMINE OXIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VENLAFAXINE |
| Therapeutic Class | SELECTIVE SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBI |
| Indications | Depression, social anxiety disorder and panic. |
| Caution | Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, sexual dysfunction, asthenia, sweating, and ervousness. |
| Dose Range |
Depression: Initial daily dose of venlafaxine 75 mg in two or three divided doses. Anxiety : 75 mg once daily. Panic Disorder: 37.5mg for 7 days increasing to 75mg daily |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |